SCHEMBL66565

SCHEMBL66565

CS(=O)(=O)c1ncc(Br)cn1

nearest known ligand 0.35

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 3/20 0.35
LMNA P02545 1/20 0.35
SMN1; SMN2 Q16637 1/20 0.35
ALDH1A1 P00352 3/20 0.34
HSD17B10 Q99714 2/20 0.34
NPC1 O15118 2/20 0.34
HTT P42858 2/20 0.34
TP53 P04637 1/20 0.34
MAPT P10636 1/20 0.34
XBP1 P17861 1/20 0.34
MAPK1 P28482 1/20 0.34
NPSR1 Q6W5P4 1/20 0.34
TLR9 Q9NR96 1/20 0.34
KMT2A Q03164 2/20 0.32
MEN1 O00255 1/20 0.32
PLCG1 P19174 1/20 0.32
EDNRA P25101 1/20 0.31
THRB P10828 1/20 0.31
NR1H2 P55055 1/20 0.30
PTGS1 P23219 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12562404 0.79 NPC1 (0.47) KDM4ESMN1; SMN2ALDH1A1NPC1MAPT
SCHEMBL765855 0.77 APLNR (0.41) KDM4ELMNASMN1; SMN2ALDH1A1HSD17B10
SCHEMBL1940334 0.75 TP53 (0.41) LMNASMN1; SMN2ALDH1A1HSD17B10NPC1
SCHEMBL28832576 0.75 LMNA (0.35) LMNASMN1; SMN2ALDH1A1HSD17B10NPC1
SCHEMBL7043547 0.75 APLNR (0.41) KDM4ELMNASMN1; SMN2ALDH1A1HSD17B10
SCHEMBL3210214 0.75 CA12 (0.40) KDM4ELMNASMN1; SMN2ALDH1A1HSD17B10
SCHEMBL17850503 0.75 ALDH1A1 (0.33) KDM4EALDH1A1HSD17B10HTTKMT2A
SCHEMBL19951537 0.75 NPC1 (0.33) KDM4ENPC1
SCHEMBL10582722 0.73 TP53 (0.41) LMNASMN1; SMN2ALDH1A1HSD17B10NPC1
SCHEMBL5909586 0.72 LMNA (0.31) LMNASMN1; SMN2ALDH1A1HSD17B10NPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 86 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-122039076-A Preparation method of 2-methyl sulfoxide pyrimidine derivative 石河子大学 2026-05-15 CN disclosed
US-20260124204-A1 METALLOENZYME INHIBITOR COMPOUNDS EIKONIZO THERAPEUTICS, INC. (US) 2026-05-07 US disclosed
US-12370194-B2 Metalloenzyme inhibitor compounds EIKONIZO THERAPEUTICS, INC. (US) 2025-07-29 US disclosed
US-12139497-B2 Aryl, heteroaryl, and heterocyclic compounds for treatment of medical disorders ACHILLION PHARMACEUTICALS, INC. (US) 2024-11-12 US disclosed
US-20240307391-A1 METALLOENZYME INHIBITOR COMPOUNDS EIKONIZO THERAPEUTICS, INC. (US) 2024-09-19 US disclosed
US-11938134-B2 Metalloenzyme inhibitor compounds EIKONIZO THERAPEUTICS, INC. (US) 2024-03-26 US disclosed
WO-2023208151-A1 USP INHIBITOR, PREPARATION METHOD THEREFOR, AND APPLICATION 北京华森英诺生物科技有限公司 2023-11-02 WO disclosed
US-20230287005-A1 ARYL, HETEROARYL, AND HETEROCYCLIC COMPOUNDS FOR TREATMENT OF MEDICAL DISORDERS ACHILLION PHARMACEUTICALS, INC. 2023-09-14 US disclosed
US-20230287005-A1 ARYL, HETEROARYL, AND HETEROCYCLIC COMPOUNDS FOR TREATMENT OF MEDICAL DISORDERS ACHILLION PHARMACEUTICALS, INC. 2023-09-14 US disclosed
US-20230287005-A1 ARYL, HETEROARYL, AND HETEROCYCLIC COMPOUNDS FOR TREATMENT OF MEDICAL DISORDERS ACHILLION PHARMACEUTICALS, INC. 2023-09-14 US disclosed
EP-1802632-A1 THIENO-PYRIMIDINE COMPOUNDS HAVING FUNGICIDAL ACTIVITY Dow AgroSciences LLC (US) 2007-07-04 EP disclosed
WO-2006047397-A1 THIENO-PYRIMIDINE COMPOUNDS HAVING FUNGICIDAL ACTIVITY DOW AGROSCIENCES LLC (US) 2006-05-04 WO disclosed
US-20060089370-A1 Thieno-pyrimidine compounds having fungicidal activity BREWSTER WILLIAM K 2006-04-27 US disclosed
US-20040254186-A1 Pyridylfurans and pyrroles as raf kinase inhibitors SMITHKLINE BEECHAM P.L.C. (GB) 2004-12-16 US disclosed
EP-1432697-A1 PYRIDYLFURANS AND PYRROLES AS RAF KINASE INHIBITORS SMITHKLINE BEECHAM PLC (GB) 2004-06-30 EP disclosed
WO-2003022833-A1 PYRIDYLFURANS AND PYRROLES AS RAF KINASE INHIBITORS SMITHKLINE BEECHAM PLC (GB) 2003-03-20 WO disclosed
CN-1085280-A The manufacture method of modified form fibrous material and colouring method thereof HOECHST AG (DE) 1994-04-13 CN disclosed
EP-0033195-B1 PYRIMIDINE-2-SULPHIDES AND THEIR S-OXIDES FOR USE IN MEDICINE, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM, PROCESSES FOR THEIR PREPARATION AND SUCH COMPOUNDS WHEN NOVEL PER SE NYEGAARD & CO. A/S (NO) 1985-12-04 EP disclosed
US-4423047-A INHIBITING ABNORMAL CELL PROLIFERATION NYEGAARD & CO. A/S (NO) 1983-12-27 US disclosed
EP-0033195-A1 Pyrimidine-2-sulphides and their S-oxides for use in medicine, pharmaceutical compositions containing them, processes for their preparation and such compounds when novel per se NYEGAARD & CO. A/S (NO) 1981-08-05 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230287005-A1 ARYL, HETEROARYL, AND HETEROCYCLIC COMPOUNDS FOR TREATMENT OF MEDICAL DISORDERS CFD, F12, F3 KDM4E 4286/4885LMNA 1087/4885SMN1; SMN2 2201/4885
US-20060089370-A1 Thieno-pyrimidine compounds having fungicidal activity TYMP, DPM1, TYMS KDM4E 1522/4885LMNA 4344/4885SMN1; SMN2 1805/4885
US-20240307391-A1 METALLOENZYME INHIBITOR COMPOUNDS HDAC6, HDAC1, HDAC2 KDM4E 2837/4885LMNA 4039/4885SMN1; SMN2 447/4885
US-20260124204-A1 METALLOENZYME INHIBITOR COMPOUNDS HDAC6, HDAC3, HDAC1 KDM4E 1855/4885LMNA 3751/4885SMN1; SMN2 2245/4885
US-11938134-B2 Metalloenzyme inhibitor compounds HDAC6, HDAC1, HDAC2 KDM4E 2837/4885LMNA 4039/4885SMN1; SMN2 447/4885
US-12139497-B2 Aryl, heteroaryl, and heterocyclic compounds for treatment of medical disorders CFD, F12, F3 KDM4E 4387/4885LMNA 1125/4885SMN1; SMN2 2468/4885
US-20040254186-A1 Pyridylfurans and pyrroles as raf kinase inhibitors BRAF, ARAF, RAF1 KDM4E 1466/4885LMNA 1591/4885SMN1; SMN2 2046/4885
US-12370194-B2 Metalloenzyme inhibitor compounds HDAC6, HDAC1, HDAC2 KDM4E 2837/4885LMNA 4039/4885SMN1; SMN2 447/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.